Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.
Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback